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ABSTRACT  
Purpose: There is no ‘gold standard’ measure for moderate to vigorous physical activity 
(MVPA) (11); some error is inherent to self-report and device-based measures. Few studies 
have examined agreement between self-report and device-based measures in the intervention 
trial context or whether the difference between measures is influenced by intervention 
participation. 
Methods: MVPA was measured at baseline and 6-months by Active Australia survey (AAS) 
and GT1M accelerometer (≥ 1952 counts/minute) in the intervention (n =135) and usual care 
control (n =141) participants of a randomized trial targeting weight loss by MVPA increases 
and energy intake reductions in adults with type 2 diabetes. Agreement, for each group at 
each assessment, was examined using the Bland-Altman approach and regression based 
modelling. As the differences between MVPA measures varied with average values ([AAS + 
GT1M]/ 2), they were examined as a percentage of average physical activity. T-tests were 
used to assess unadjusted group differences and changes over time. Analysis of covariance 
models tested intervention effects on measurement error at follow-up, adjusted for baseline.  
Results: Agreement worsened, and variability in the difference measures became greater, as 
the average amount of MVPA increased. Measurement error differed significantly between 
groups at follow-up (P = .010) but not baseline (P = .157) and changed significantly within 
the intervention group (P = .001) but not the control group (P = .164). There was a 
statistically significant effect of the intervention on measurement error (P = .026).  
Conclusions: Measurement error of self-report relative to accelerometer= appeared to be 
affected by intervention. As measurement error cannot be definitively attributed to self-report 
or accelerometer, it would be prudent to measure both in future studies.   
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INTRODUCTION  
Paragraph Number 1 Physical inactivity is a modifiable risk factor for chronic diseases 
including type 2 diabetes, cardiovascular disease, and some cancers. The development of 
effective, broad reaching physical activity interventions is a population health priority and in 
order to properly evaluate such interventions, valid and reliable measures are needed. There 
is no ‘gold standard’ measure for moderate-to-vigorous physical activity (MVPA) (11); 
interventions most commonly use self-report but increasingly incorporate objective 
monitoring. A systematic review (17) has shown self-report typically has only low to 
moderate correlations with measures from monitoring devices, including accelerometers, and 
can yield much lower or higher estimates of physical activity than monitoring devices. The 
substantial disagreement between self-report and objective monitoring has implications for 
estimating intervention effects, as there is reason to suspect measurement error may be 
differential between intervention and control groups after intervention (22). 
Paragraph Number 2 A study of adolescent girls (22) observed measurement error (self-
report relative to accelerometer) was differential at follow-up but not at baseline and explored 
social desirabiltiy bias as a possible reason. Social desirability bias may cause interventions 
to appear more effective by self-report than they really were if, after intervention, participants 
who have received an intervention that involves intensive contact with intervention staff are 
more inclined to report their behavior in a socially desirable manner than controls who have 
had minimal or no contact with staff. Self-report may alternatively underestimate intervention 
effects, for example, if certain intervention components (e.g., self-monitoring) increase 
intervention participants’ awareness of their physical activity and thereby selectively improve 
their reporting accuracy (i.e, reduce their over-reporting) (23, 26). Further, disagreement 
between self-report and accelerometer may be altered by interventions that increase physical 
activity as it is often reported to be worse at higher levels of physical activity than at lower 
levels (2, 9, 21).  
Paragraph Number 3 Whether measurement error is impacted by intervention in adults, and 
the implications this has for trial outcomes remains to be established. In the context of a 
behaviorally based weight loss intervention trial (10), we examined the agreement between 
self-reported and accelerometer-measured MVPA at baseline and 6-months within the control 
and intervention groups. We further examined variation over time, differences between 
groups and intervention effects on the difference between the measures of MVPA. We also 
examined the potential implications of any alteration in measurement error over the course of 
the intervention by comparing the trial’s intervention effects according to self-report and 
accelerometer. 
 
METHODS 
Paragraph Number 4 This study uses data from Living Well with Diabetes (LWWD), a 
randomized controlled trial of a telephone-delivered weight loss intervention targeting 
increased physical activity and reductions in energy intake. The study protocol has been 
reported previously (10). Recruitment of primary care practices commenced in October 2008 
with participant recruitment occurring between February 2009 and April 2011. Data 
collection occurred at baseline and 6 months and is ongoing for 12-, 18- and 24-months. 
Informed consent was obtained from all participants and the University of Queensland 
Behavioral and Social Sciences Ethics Review Committee granted ethics approval for the 
trial. 
Paragraph Number 5 Nine general practices were recruited in Logan, a diverse 
socioeconomic area approximately 30km south of Brisbane, Australia. Within practices, 1407 
eligible patients (i.e., diagnosed type 2 diabetes, aged 20 - 75 years, and having a listed 
telephone number) were identified using electronic medical records. Patients not excluded by 
GP screening for contraindications to unsupervised physical activity (n = 908) were posted 
study materials by the GP and were followed up by study staff to determine eligibility and 
solicit informed consent unless they had declined further contact (n = 206). To be eligible, 
participants needed to be overweight or obese (Body Mass Index, BMI ≥ 25.0 kg/m2) (28) or 
inactive (< 5 days per week of ≥ 30 minutes of MVPA) (3) and could not report: current 
cancer treatment other than endocrine therapy; prior or planned bariatric surgery; use of 
weight loss medications (e.g., Orlistat) or communication difficulties relevant to receiving the 
intervention. Of those reached by telephone and deemed eligible (n = 420), 302 (71.9%) 
agreed to participate, completed the baseline assessment and were randomized to receive 
either Telephone Counseling (n = 151) or Usual Care (n = 151). Randomization was by the 
minimization method (1, 19) using the MINIM program 
(www.sghms.ac.uk/depts/phs/guide/randser.htm), aiming to balance treatment groups across 
the following prognostic factors (without weighting for importance): gender; age (≥ 55 
years); BMI (≥ 40 kg/m2); HbA1c (≥ 8%); self-reported MVPA (≥ 150 minutes and ≥ 5 days 
per week); and, diabetes management (insulin or combination therapy / traditional oral 
hypoglycaemic medications / new diabetes agents, i.e. Exenatide or Sitagliptin / lifestyle 
alone).  
Telephone Counseling Weight Loss Intervention 
Paragraph Number 6 Intervention participants were assigned at least 14 calls over the 
intensive first 6-months of an 18-month telephone-delivered weight loss counseling 
intervention, described in detail elsewhere (10). Participants were provided with a detailed 
workbook, pedometer, a self-monitoring ‘tracker’ to record daily physical activity and food 
intake and detailed feedback after each assessment that highlighted discrepancies between 
their reported behavior (including physical activity) and the study targets. The physical 
activity target was at least 210 minutes of planned, moderate-intensity physical activity per 
week (≥ 30 minutes per day every day). A further two to three resistance training sessions per 
week were also recommended.  
Usual Care  
Paragraph Number 7 Following each assessment, participants in the control group received 
publically available brochures addressing health behaviors important for diabetes self-
management (e.g., losing weight, alcohol consumption) and a letter thanking them for their 
participation. The letter included brief feedback summarizing their assessment results, 
including their physical activity levels, but avoided any comparison with recommendations. 
The attention provided to the control group was designed to minimize attrition.  
Data Collection and Processing 
Paragraph Number 8 Self-reported physical activity. Self-reported physical activity was 
assessed by Computer Assisted Telephone Interview (CATI) using the Active Australia 
Survey (AAS), an eight-item questionnaire that is used extensively in Australian research (4). 
Participants were asked to report the total time engaged in gardening, walking (for ≥ 10 
minutes at a time), moderate- and vigorous-intensity physical activities in the past week. Data 
were processed according to the AAS protocol (4), but without doubling of the duration of 
vigorous activity, to facilitate comparability with the accelerometer data. Total weekly 
MVPA was calculated as the summed durations of walking, moderate-, and vigorous-
intensity activities (excluding gardening), first truncating each activity at 840 minutes/week 
and truncating total MVPA at 1680 minutes/week. In assessing duration of MVPA, the AAS 
has test-retest reliability that is comparable with the U.S. Behavioral Risk Factor Surveillance 
Survey and the International Physical Activity Questionnaire (9), has acceptable agreement 
with these measures (7) and moderate correlation with accelerometer, ranging from 0.29 
(95% CI: 0.16, 0.41) (24) to 0.52 (95% CI not reported) (8). Intra-class correlations reported 
for test-retest range from 0.32 (95% CI: 0.09, 0.52) (16) to 0.64 (95% CI: 0.57, 0.70) (9).  
Paragraph Number 9 Accelerometer measurement of physical activity. Actigraph GT1M 
accelerometers (Actigraph, LLC, Fort Walton Beach, Florida), worn on elasticized belts 
around participants’ waists, positioned on the right mid-axillary line, were used to monitor 
MVPA objectively. Participants were instructed to wear the accelerometers during all waking 
hours for seven consecutive days, except during water-based activities (e.g., showering, 
swimming). The accelerometers were set to collect data in 60-second epochs. Participants 
reported the times the accelerometer was donned and removed each day in a wearing log. 
Research staff identified non-wear periods by comparing participants’ log data with the 
precise times movement began and ceased, to overcome limitations in relying exclusively on 
wear-time algorithms (27) or self-report. Days were considered valid that had at least 10 
hours of wear and no implausibly high counts (≥ 20,000 counts per minute; cpm). 
Accelerometer compliance was good, with almost all participants providing at least four valid 
days of wear (98.1% at baseline and 97.1% at 6-months). Mean (± Standard Deviation, SD) 
wear time on valid days was 13.5 ± 1.7 hours/day at baseline and very similar at 6-months 
(13.7 ± 1.7 hours/day). A program adapted from the National Cancer Institute was used to 
process and summarise the data (15). For each valid day, MVPA was identified as the 
number of minutes at or above the commonly used cutpoint of 1952 cpm (12). Average 
MVPA on valid days was multiplied by 7 to yield a weekly estimate. Sensitivity analyses 
examined alternative MVPA classifications: one of the lowest (≥ 574 cpm) and highest 3-
MET cutpoints for MVPA (≥ 2743 cpm) (25).  
Paragraph Number 10 Anthropometric and demographic measures. Anthropometric and 
demographic data were collected at baseline. BMI was determined from nurse-assessed 
height and weight; demographic information was collected via CATI by research staff 
blinded to study group allocation (10).  
Statistical Analyses  
Paragraph Number 11 Data analyses were performed in SPSS (IBM SPSS v.20; SPSS) and 
significance was set at P < 0.05. Analyses included the n = 272 participants with physical 
activity data from both self-report and accelerometer at both baseline and 6-months. 
Agreement of self-report with accelerometer MVPA was assessed using the Bland-Altman 
approach. Scatterplots depicting the differences between measures (AAS - GT1M) across the 
average value of the two measures ([AAS + GT1M]/2) (5) were created separately for each 
group at each time point. As regression (5, 6) showed mean differences and variability both 
increased significantly (P < 0.05) with average values, and log-transformation failed to 
resolve this issue, the scatterplots show mean differences and 95% Limits of Agreement 
(LoA) in terms of the regression equations. For this same reason, when examining changes, 
group differences and intervention effects on measurement error, the difference between the 
MVPA measures was examined as a percentage of average values (100x[AAS - GT1M]/ 
[AAS + GT1M]/2). This outcome followed an approximately normal distribution. Unadjusted 
differences between groups in means (systematic error) were examined using independent 
samples T-tests; Levene’s test was used to test differences between groups in variance 
(random error). Changes over time within groups were examined by paired t-tests.  
Paragraph Number 12 Analysis of covariance (ANCOVA) models were used to examine 
intervention effects in terms of group differences in measurement error at follow-up, adjusted 
for baseline measurement error. To examine the potential impact of measurement error on 
results from the intervention, the trial’s intervention effects for MVPA by self-report and by 
accelerometer are reported. While AAS and GT1M data were skewed, change scores (6-
months minus baseline) approximated normality. ANCOVA models examined change in 
MVPA, adjusted for baseline MVPA. From these models, group differences and the adjusted 
mean change within groups are reported, with 95% Confidence Intervals (CI). All models 
showed minimal non-normality and heteroscedascicity. Sensitivity analyses were conducted 
to examine whether the main study conclusions regarding changes, group differences or 
intervention effects on measurement error were robust across a wide range of potential 
cutpoints for MVPA. 
RESULTS 
Participants 
Paragraph Number 13 Characteristics of study participants are presented in Table 1. Trial 
participants had a mean (± Standard Deviation, SD) age of 58.3 (± 8.6) years, were nearly all 
either overweight (26.2%) or obese (68.2%), mostly Caucasian (87.4%) and were more 
commonly male (56.3%) than female. Median duration of diabetes was five years (25th, 75th 
percentile: 2, 10 years). The trial had a high response rate (72% of those reached and eligible) 
and participants did not differ from non-participants on most variables (see Table, SDC 1, 
comparison of study participants with non-participants on demographic, health, and 
behavioral characteristics), however, participants had significantly higher BMI, shorter 
diabetes duration, more education, and were under-represented by ex-smokers and over-
represented by never smokers. Loss to follow-up was low (12.6% intervention and 7.3% 
control) and was non-differential. Most characteristics did not differ between those with 
complete (n = 272) and incomplete data (n = 30) (see Table, SDC 2, comparison of 
completers with those missing 6-month study outcomes); the only statistically significant 
differences were for use of insulin (P = 0.023) and for smoking status (P = 0.036), with those 
on insulin and current smokers tending to lack follow-up data. 
INSERT TABLE 1 ABOUT HERE 
Agreement of the AAS with GT1M at Baseline and Six Months 
Paragraph Number 14 The Bland-Altman plots (Figure 1 a-d) show the agreement of self-
reported MVPA (AAS) with accelerometer-measured MVPA (GT1M) at baseline in a) 
intervention and b) control groups and at 6-months in c) intervention d) control. For each 
group at each time point, as the average value of the two measures ([AAS + GT1M]/2) 
increased, the mean difference (AAS - GT1M) and the variability in the differences also 
increased significantly (all comparisons P < 0.05). This can be seen in all four plots in the 
slope of the lines for the mean differences and 95% LoA, which respectively increase, and 
widen, as average values increase. The mean differences and 95% LoA indicated substantial 
differences between self-report and accelerometer, however the plot for the intervention 
group at follow-up showed smaller mean differences and narrower limits of agreement than 
the other plots. For example, Panel a (Figure 1) shows that for the intervention group at 
baseline, we would expect a mean difference of 104.1 minutes/week (i.e. 68.1 + 0.6x60) with 
95% LoA of -190.5 to 120.2 minutes/week for those with 60 minutes/week as their average 
MVPA ([AAS + GTIM]/2) and a much larger mean difference (194.1 minutes/week) and 
wider LoA (-445.5 to 540.2 minutes/week) in those with much higher physical activity levels 
(average values of 210 minutes/week). By contrast at follow-up in the intervention group, the 
mean differences and LoA were much smaller for a given amount of average MVPA, e.g., 
19.9 (95% LoA: -187.7, 195.8) minutes/week for those with average values of 60 
minutes/week and 49.9 (95% LoA: -292.7, 360.8) minutes/week for those with average 
values of 210 minutes/week.  
INSERT FIGURE 1 ABOUT HERE 
Effect of the Intervention on Measurement Error (Difference Between AAS and GT1M) 
Paragraph Number 15 According to unadjusted findings, measurement error (as a 
percentage of average MVPA) showed no evidence of change between baseline and 6-month 
follow-up within the control group (p = .164), but it did change from approximately 19% 
lower to 10% higher within the intervention group (P = .001; Table 2). While there was no 
evidence of a difference between groups in mean measurement error at baseline (P = 0.157), 
at follow-up the mean measurement error differed significantly between groups (P = 0.010). 
The difference was such that at follow-up control group participants reported significantly 
less activity than was measured by accelerometer (-24.2%, 95% CI: -43.7, -4.7), but 
intervention participants did not do so (10.3, 95% CI: -6.7, 27.3). Coinciding with the 
differences in mean measurement error, at baseline there was no evidence of a difference 
between groups in the variability in measurement error (as percentage of average values; P = 
.497), while at follow-up, the variability in measurement error was significantly less for the 
intervention than the control group (P = .037). ANCOVA models showed a significant 
intervention effect for measurement error. At follow-up, adjusted for baseline, the 
intervention and control groups differed significantly in measurement error (mean difference 
for intervention-control = 28.0% of average MPVA, 95% CI: 3.3, 52.7, P = 0.026). As with 
the unadjusted results, the adjusted means showed the self-report to be significantly lower 
than accelerometer measures in the control group (-21.0% of average values, 95% CI: -38.2, -
3.9), but not in the intervention group (6.9 % of average values, 95% CI: -10.7, 24.6). 
INSERT TABLE 2 ABOUT HERE 
Sensitivity Analyses 
Paragraph Number 16 Results of the sensitivity analyses (Table 2) showed that the 
definition of accelerometer MVPA had a dramatic impact on whether self-report tended to 
under- or over-estimate relative to accelerometer and some impact on study conclusions 
regarding whether measurement error varied by group, over time, or was impacted by the 
intervention. The least discrepancy between self-report and accelerometer was seen in the 
main analysis. Self-report consistently significantly underestimated relative to the 
accelerometer when using the very low cutpoint for MVPA, by an unrealistic amount (i.e. up 
to 7 times the average amount of MVPA). Self-report consistently significantly overestimated 
relative to accelerometer when using the highest cutpoint for MVPA. Significant changes 
over time in the intervention group and significant differences between groups at follow-up 
(unadjusted) were replicated with both lower and higher MVPA cutpoints, however 
significant control group changes in measurement error were seen with high and low 
cutpoints (but not the main analysis). The intervention effect on measurement error was 
significant in the main analysis and using the low cutpoint (P < .001), but not using the high 
cutpoint for MVPA (P = 0.083). 
Intervention Effects for Physical Activity by Self-report and Accelerometer 
Paragraph Number 17 Adjusted for baseline values, significant mean changes in MVPA 
(minutes/week) within the intervention group were slightly less according to the 
accelerometer (44.4, 95% CI: 25.0, 63.9) than self-report (72.3, 95% CI: 42.0, 102.6) (see 
Table, SDC 3, effect of the intervention on MVPA measured by the AAS and GT1M 
accelerometer). However, the non-significant changes within the control group tended to be 
less according to accelerometer (1.5, 95% CI: -17.4, 20.4) than by self-report (19.6, 95% CI: -
10.1, 49.2), resulting in intervention effects that appeared only slightly smaller for 
accelerometer-measured MVPA (42.9, 95% CI: 15.5, 70.1, P = .002) than for self-reported 
MVPA (52.7, 95% CI: 10.4, 95.1, P = .015).  
 
DISCUSSION 
Paragraph Number 18 Self-report has limited agreement with accelerometer physical 
activity (18). For trial results to be unbiased in spite of measurement error requires that the 
error remain constant over the study duration and be equal across treatment groups. This 
study observed a significant intervention effect on measurement error (of self-report relative 
to accelerometer) in adults, and provided some evidence that measurement error can vary 
significantly over the course of an intervention and is not equal for intervention and control 
groups at follow-up. The caution that measurement error relative to accelerometer may not be 
constant over time and non-differential by group is likely to apply across the vast majority of 
cutpoints used to assess MVPA in the literature, as both very low and very high cutpoints for 
MVPA replicated  the changes over time within the intervention group and the group 
differences at follow-up (unadjusted), and the observed intervention effect on measurement 
error significant both in the main analysis and with the low MVPA cutpoint. 
Paragraph Number 19 This trial’s findings add to the few prior studies that have reported 
on potential changes between pre- and post- intervention in the correlation of self-report with 
device-based MVPA measures in adults (14, 20, 22). Two studies have noted a weakening in 
correlation over the course of the intervention, within both treatment groups combined (14, 
20). Another has observed a strengthening in correlation within the control group and no 
change in correlation for the intervention group (22). However, correlations are not sensitive 
to shifts in systematic error. The studies suggest random error may vary over time during 
interventions, with the present study providing further evidence suggestive that systematic 
error (mean differences) also cannot safely be assumed to remain constant during 
intervention.  
Mechanisms for Variation in Physical Activity Measurement Error 
Paragraph Number 20 This study, and others comparing self-report MVPA with 
accelerometer (2, 7, 21), have noted both systematic error (mean differences) and random 
error (limits of agreement) increase with average MVPA (average of self-report and 
accelerometer). This may contribute to the patterning of measurement error over the 
intervention, which was largely consistent with the patterning of physical activity, i.e., 
increases in the intervention group (but not in controls) and differences between groups at 
follow-up (but not baseline). Observations from the study regarding random error (seen in the 
limits of agreement and the variability in measurement error) were consistent with the idea 
that intervention participants may experience improved reporting accuracy after exposure to 
intervention, which included self-monitoring and education on what constitutes “moderate” 
and “vigorous” physical activity.  
Paragraph Number 21 Issues with self-report measurement, such as misinterpretation of the 
survey questions, inaccurate recall, and/or social desirability bias and issues with using 
accelerometers in free-living populations could both contribute to the measurement error 
observed in this study. The mean differences, although substantial, may or may not reflect 
under- or over-reporting by participants, as the direction of the mean differences was very 
sensitive to the choice of accelerometer data treatment and therefore could just as easily 
represent over- or under- detection of MVPA by the accelerometer. Despite their regular use 
as referent assessment methods in validity studies, accelerometers are not a gold standard for 
physical activity measurement. The proportional increase in measurement error with 
increasing amount of physical activity could arise from errors in self report, if, for example, it 
is easier for inactive participants to recall and report infrequent, discrete bouts of physical 
activity than it is for active participants to recall physical activity that is completed often, and 
which may be variable in terms of duration, frequency and domain. The approach of applying 
cutpoints to define MVPA from accelerometer data could also explain the proportionality. 
Cut points are derived from equations that use accelerometer counts to predict energy 
expenditure (13), and do so very accurately for treadmill-based activities but poorly for 
activities of daily living (13). The imperfect sensitivity and specificity of any cutpoint for 
detecting each true minute of MPVA will naturally lead to an increase in the total amount of 
error (in minutes) as the prevalence of true minutes of MVPA increases. Type of activity may 
also be relevant as the most active participants may also be the most likely to engage in 
activities that are not well captured by accelerometers (such as cycling and swimming).  
Implications for Physical Activity Interventions 
Paragraph Number 22 The evidence supporting that measurement error may be affected by 
intervention, may vary over time and may be differential by treatment allocation has 
implications for comparing results from trials that use self-report exclusively with trials that 
use accelerometers. In the LWWD trial, physical activity changes over time within groups 
and intervention effects were slightly larger when measured by self-report than by 
accelerometer, with an additional mean change of 18.1 minutes/week for controls, 27.9 
minutes/week for intervention participants and an additional 9.8 minutes/day for the 
intervention effect. Both measures led to the same conclusions regarding statistical 
significance, however, the discrepancy in effect size was sufficient to classify change as 
clinically relevant in the intervention group by self-report and not by accelerometer, using the 
LWWD a priori  ≥ 60 minutes/week definition. The only other trial to compare intervention 
effects obtained by self-report (7-day physical activity recall) with accelerometer (the RT3 
triaxial monitor) for the same sample of study participants (20) similarly found no difference 
to the statistical conclusions regarding intervention effects (i.e., both not significant) but 
tended to see intervention effects more in favour of the intervention group and larger changes 
within both intervention and control groups  by self-report measures than by accelerometer 
measures. The results of physical activity trials may appear slightly more promising using 
self-report than using accelerometers, although with bias potentially arising from either 
measurement tool, it remains unknown whether results are exaggerated by self-report or 
understated by accelerometers.  
Limitations 
Paragraph Number 23 It should be noted that the trial was not designed and powered to 
detect intervention effects on measurement error and resulted in effects with wide 95% 
confidence intervals. Further examination in larger trials may reveal more precise evidence 
regarding the extent to which measurement error is affected by intervention. The 
accelerometer monitoring period was scheduled without consideration of the AAS recall 
period; this is unlikely to affect conclusions regarding intervention effects on measurement 
error, as the scheduling was consistent over time and for both groups, but may have 
weakened the overall extent of agreement seen in this study. Importantly, as both intervention 
and control participants knew their activity was being monitored objectively, some biases in 
reporting may have been minimized in this study (e.g., such as those evidenced by sizeable 
self-reported improvements in unmonitored control groups). Thus, the extent of discrepancy 
of self-report against accelerometer in this study may be an understatement of the potential 
discrepancy between findings from interventions that use self-report (without objective 
monitoring) versus interventions that use accelerometers. 
Conclusion 
Paragraph Number 24 This trial showed evidence that measurement error of self-report 
(Active Australia Survey) relative to accelerometer was substantial and was impacted by 
intervention, either directly or indirectly through impact of intervention on amount of 
physical activity. As a result, intervention trial outcomes were estimated as slightly stronger 
by self-report than by accelerometer. With errors in either or both assessment tools 
potentially contributing to these findings, it would be prudent for interventions to measure 
physical activity with both self-report and device-based measures.  
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FIGURE 1 - Bland Altman plots of the difference between self-reported MVPA (Active 
Australia Survey AAS) and accelerometer (GT1M) across average values (mean of AAS and 
GT1M) at baseline for a) intervention and b) control and at 6-months for c) intervention and 
d) control. 
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TABLE 1. Baseline characteristics of study participants randomized to Telephone Counseling 
(n = 151) and Usual Care (n = 151). 
 Telephone 
Counseling 
(n=151) 
 Usual care 
(n=151) 
 
 
All  
(n=302) 
Age, years, mean (SD)    57.7 (8.1) 
 
  58.3 (9.0)    58.0 (8.6) 
Male, n (%)   84 (55.6) 
 
  86 (57.0)  170 (56.3) 
Body Mass Index, mean (SD)   33.1 (6.3) 
 
  33.2 (6.0)    32.3 (6.1) 
Duration diabetes, years, median 
(25th, 75th percentile) 
    4 (2, 7)     5 (2, 10)      5 (2, 10) 
Diabetes medication a 
   
  
   Traditional OHAs, n (%) 114 (75.5) 
 
119 (78.8)  233 (77.2) 
   Insulin, n (%)   23 (15.2) 
 
  20 (13.2)    43 (14.2) 
   New agents, n (%)     7 (4.6) 
 
    5 (3.3)    12 (4.0) 
Other chronic conditions 
   
  
   CVD related condition, n (%) 127 (84.1) 
 
113 (74.8)  240 (79.5) 
   Musculoskeletal condition, n (%)   51 (33.8) 
 
  50 (33.1)  101 (33.4) 
   Lung condition, n (%)   14 (9.3) 
 
  18 (11.9)    32 (10.6) 
Smoking status, n (%)     
   Never smoker    77 (51.0)    67 (44.4)  144 (47.7) 
   Ex-smoker   60 (49.7)    67 (44.4)  127 (42.1) 
   Current smoker   14 (9.3)    17 (11.3)    31 (10.3) 
Born in Australia, n (%)   99 (65.6) 
 
108 (71.5)  207 (68.5) 
Caucasian, n (%) 131 (86.8) 133 (88.1)  264 (87.4) 
Employment, n (%)      
   Full-time/Part-time or casual   97 (64.3) 
 
  93 (61.6)  190 (62.9) 
   Retired   40 (26.5)   42 (27.8)    82 (27.2) 
   Other   14 (9.3)    16 (10.6)    30 (9.9) 
Income <$1000/week, n (%)    49 (32.5) 
 
  61 (40.4)  110 (36.4) 
< High school education, n(%)     9 (6.0) 
 
  26 (17.2)    35 (11.6) 
HbA1c, median (25th, 75th 
percentile) 
    7.6 (6.3, 8.5)   7.0 (6.4, 7.9)    7.1 (6.4, 8.0) 
Energy intake, mean (SD)     7.1 (2.3)      6.9 (2.2)      7.0 (2.2) 
Diet Quality (0-100), mean (SD)   65.6 (13.6)    65.5 (10.7)    65.6 (11.0) 
Physical activity, mins/week, 
median (25th, 75th percentile) 
     
Self-report b   90.0  
 (20.0, 160.0) 
 
  75.0  
 (0.0, 200.0) 
 
 
Accelerometer c   93.5  
(28.8, 151.9) 
 
  92.2  
(39.2, 185.1)  
  92.7  
(38.4, 180.5) 
a OHAs = oral hypoglycaeamic medications; new agents = glucagon-like peptide-1 receptor 
agonists (e.g. Exenatide) or dipeptidyl peptidase-4 inhibitors (e.g. Sitagliptin) 
b Active Australia Survey walking, moderate and vigorous activity, without doubling of the 
vigorous component 
c Time spent at >=1952 counts per minute, Actigraph GT1M accelerometer 
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TABLE 2. Effect of the intervention on the difference in moderate-to-vigorous physical activity (MVPA) between the Active Australia Survey 
(AAS) and GT1M accelerometer as a percentage of average MVPA, using three different cutpoints for MVPA. 
  Telephone Counseling (n=132)  Usual Care (n=140)  Telephone Counseling – Usual Care 
 Mean (95% CI)  Mean (95% CI)  Mean (95% CI)  P
 a 
Freedson (≥1952 counts/minute) 
 
 
 
 
 
 
 Baseline      -19.2 (-39.6, 1.2)       -40.1 (-60.5, -19.7)   20.9 (-8.1, 49.9)   0.157 
6-months       10.3 (-6.7, 27.3)**       -24.2 (-43.7, -4.7)  34.5 (8.5, 60.5)    0.010
c 
6-months, adjusted for baselineb         6.9 (-10.7, 24.6)       -21.0 (-38.2, -3.9)  28.0 (3.3, 52.7)   0.026 
Sensitivity analyses        
Low MVPA cutpoint (≥574 cpm) 
 
 
 
 
 
 
 Baseline    -144.5 (-153.8, -135.1)     -149.1 (-158.0, -140.2)    4.6 (-8.4, 17.5)   0.487 
6-months    -542.3 (-607.9, -476.7)***   -713.7 (-789.3, -638.0)***   171.4 (70.8, 272.0)    0.001
c 
6-months, adjusted for baseline b    -547.9 (-617.1, -478.8)     -708.3 (-775.5, -641.1)   160.4 (63.9, 256.9)   0.001 
High MVPA cutpoint (≥2743 cpm)d 
 
 
 
 
 
 
 Baseline     108.7 (95.6, 121.8)        95.7 (81.8, 109.6)       13.0 (-6.2, 32.2)   0.185 
6-months       75.5 (57.4, 93.5)***        45.1 (22.5, 67.7)***       30.4 (1.4, 59.5)    0.040
c 
6-months, adjusted for baseline b       72.7 (52.4, 93.0)        47.7 (28.0, 67.4)  25.0 (-3.3, 53.3)   0.083 
a P for difference between groups (independent samples t-test or ANCOVA) 
b Adjusted means (95% CIs) and P-value from Analysis of Covariance, adjusted for baseline values, with the outcome being difference between 
measures as a percentage of physical activity performed at 6-months, i.e. 100*(AAS- GT1M)/(AAS+GT1M/2) 
c Levene’s test significant at P < 0.05; equal variance not assumed in t-test 
 d The outcome was modelled adding a small constant (0.001) to AAS and GT1M data due to values of zero average physical activity, i.e. 
outcome = 100*(AAS- GT1M)/([AAS+GT1M+0.002]/2) 
* P < .05 **P < .01 ***P < .001 for change from baseline (paired t-test) 

SUPPLEMENTAL TABLE 1. Comparison of study participants with non-participants on 
demographic, health, and behavioral characteristics. 
  Non-participants  Participants 
(n = 302) 
 P a 
 n  value 
Age, years, mean (SD) 111  58.4 (10.3)    58.0 (8.6)   .681 
Male, n (%) 115   58 (50.4)  170 (56.3)   .322 
Non-participant Questionnaire        
BMI (self-report), mean (SD)  64   30.6 (4.8)    32.3 (6.1)   .040 
Self-report diabetes management,  
n (%)b        
   Insulin  63 
 
 12 (19.0)    44 (14.6) 
 
 .441 
   Traditional OHAs  63 
 
 43 (68.3)  231 (76.5) 
 
 .200 
   New agents  63 
 
   2 (3.2)      7 (2.3) 
 
 .657 
   Lifestyle only  63 
 
 11 (17.5)    55 (18.2) 
 
>.999 
Born in Australia, n (%)  63 
 
 35 (55.6)  207 (68.5) 
 
 .057 
Caucasian, n (%)  61 
 
 51 (83.6)  264 (87.4) 
 
 .411 
3+ chronic conditions, n (%)  66 
 
 46 (69.7)  184 (60.9) 
 
 .208 
Smoking status, n (%)  63 
 
   
 
<.001 
   Never smoker 
  
   5 (7.9)  144 (47.7) 
 
 
   Ex-smoker 
  
 51 (81.0)  127 (42.1) 
 
 
   Current smoker 
  
   7 (11.1)    31 (10.3) 
 
 
Employment status, n (%)  63    .173 
   Full-time/Part-time/Casual    32 (50.8)  190 (62.9)   
   Retired    21 (33.3)    82 (27.2)   
   Other    10 (15.9)    30 (9.9)   
< High School Education, n (%)  63 
 
 16 (25.4)    35 (11.6) 
 
 .008 
Income <$1000/week, n (%)  55  21 (38.2%)  110 (36.9)  .880 
Married/living together, n (%)  63 
 
 47 (74.6)  248 (82.1) 
 
 .217 
Diabetes Duration, median (25th, 75th 
percentile) 
 63 
 
   7.0  
 (4.0, 11.0)  
    5.0  
   (2.0, 10.0) 
 
 .005 
≥5 days/week of ≥30 mins PA, n (%)c  66   13 (19.7)    57 (19.0)  .864 
a P for difference between participants and non-participants by chi-square test for n (%), 
independent samples t-test for mean (Standard deviation, SD), or independent samples 
median test for median (25th, 75th percentile) 
b OHAs = oral hypoglycaeamic medications; new agents = glucagon-like peptide-1 receptor 
agonists (e.g. Exenatide) or dipeptidyl peptidase-4 inhibitors (e.g. Sitagliptin) 
c Due to missing data, n = 300 participants for days per week of at least 30 minutes of 
physical activity (PA), a single item screening question asked of most participants and in the 
non-participant questionnaire 
 
SUPPLEMENTAL TABLE 2. Comparison of completers (n = 272) with those missing 6-
month study outcomes (n = 30). 
 
 
Missing data   
(n = 30, 9.93%) 
 
Completer         
(n = 272) 
 P a 
Telephone Counseling, n (%)   19 (63.3)     132 (48.5)  .177 
Age, years, mean (SD)   58.0 (9.2)       58.0 (8.5)  .973 
Male, n (%) 
 
 13 (43.3)     157 (57.7) 
 
.174 
Diabetes management       
   Using Insulin, n (%) 
 
   9 (30.0)       34 (12.5) 
 
.023 
   Using traditional OHAs, n (%) 
 
 25 (83.3)     208 (76.5)  .496 
Diabetes duration, median (25th, 75th 
percentile) 
 
   6.0 (2.8, 10.0) 
 
      4.0 (2.0, 9.8) 
 
.172 
3+ Chronic conditions, n (%)   20 (66.7)     164 (60.3)  .559 
Smoking status, n (%)      .036 
   Never smoker   12 (40.0)     132 (48.5)   
   Ex-smoker   10 (33.3)     117 (43.0)   
   Current smoker     8 (26.7)       23 (8.5)   
Born in Australia, n (%)   20 (66.7)     187 (68.8)  .837 
Caucasian, n (%)   28 (93.3)     236 (86.8)  .396 
Income <$1000/week, n (%)   12 (40.0)       98 (36.0)  .692 
< High school education, n (%) 
 
   2 (6.7)       33 (12.1) 
 
.551 
Married/living together, n (%) 
 
 21 (70.0)     227 (83.5) 
 
.080 
Employment, n (%)      .788 
   Full-time/Part-time/casual 
 
 20 (66.7)     170 (62.5) 
 
 
   Retired     8 (26.7)       74 (27.2) 
 
 
   Other     2 (6.7)       28 (10.3) 
 
 
Body Mass Index, kg/m2, mean(SD)   33.7 (8.5)       33.1 (5.8) 
 
.683 
HbA1C, median (25th, 75th percentile)     7.6 (6.3, 8.5)        7.0 (6.4, 7.9)  .218 
Energy intake, MJ, mean (SD) 
 
   6.5 (2.1)         7.0 (2.3) 
 
.229 
Diet Quality Index, 0-100, mean (SD) 
 
 65.6 (13.6)       65.5 (10.7) 
 
.977 
Physical activity, mins/week median 
(25th, 75th percentile) 
      
   Self-report b  
 32.5  
  (0.0, 120.0) 
 
     80.0  
(20.0, 180.0) 
 
.153 
   Accelerometer c  
 93.5 
(28.8, 151.9) 
 
     92.2  
(39.2, 185.1) 
 
.847 
a P for difference between those missing data and completers by chi-square test for n (%), 
independent samples t-test for mean (Standard deviation, SD), or independent samples 
median test for median (25th, 75th percentile) 
b Active Australia Survey, without doubling of the vigorous component 
c Time spent at >=1952 counts per minute
SUPPLEMENTAL TABLE 3. Effect of the intervention on moderate-to-vigorous physical activity (MVPA) measured by the Active Australia 
Survey (AAS) and GT1M accelerometer. 
  Baseline  6-months  Change, adjusted for baseline
 a 
 Mean (SD)  Mean (SD)  Adjusted mean (95% CI) 
Self-Report 
 
 
 
 
 Telephone Counseling (n=135) 129.5 (157.5)  202.7 (195.7)  72.3 (42.0, 102.6) 
Usual Care (n=141) 132.4 (169.4)  151.0 (179.2)  19.6 (-10.1, 49.2) 
Telephone Counseling-Usual Care     52.7 (10.4, 95.1) 
Accelerometer, >=1952 counts/min       
Telephone Counseling (n=133) 125.9 (116.4)  169.9 (166.0)  44.4 (25.0, 63.9) 
Usual Care (n=140) 122.9 (115.6)  124.9 (110.4)  1.5 (-17.4, 20.4) 
Telephone Counseling-Usual Care     
42.9 (15.8, 70.1) 
a Adjusted means (95% CIs) from Analysis of Covariance, adjusted for baseline values 
 
 
